Development of vaccine formulations effective against niaid priority pathogens
Award Notice Posted
- Solicitation number
- BAA-NIAID-DMID-NIHAI2013174
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Awarded
- to Altimmune, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HHSN272201400040C Federal contract award
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- PSC
- Not on record
- Place of performance
- TBD, United States
Notice details come from SAM.gov. Updated .
Notice text
4 versions
Update #4 · Latest ·
The Infectious Disease Research Institute (IDRI) proposes to formulate, manufacture, and clinically evaluate a prophylactic TB vaccine co-lyophilized with an oil-in-water emulsion adjuvant to produce a thermostable, single-vial candidate product. The objectives, tasks, subtasks, and milestones described below are intended to achieve the goal of transforming the current two-vial liquid-based, bedside-mixed Phase 1 TB vaccine (ID93 + GLA-SE) into a dried, single-vial, thermostable vaccine. A list of deliverables and go/no-go criteria can be found in a table at the end of this document.
Update #3 ·
The objective of this contract is to support the advanced development of candidate products, which consist of a vaccine component in combination with a dry formulation technology (also referred to as solid vaccine formulations), that increase duration of stability and minimize cold chain or preservative requirements. These products will likely be used to minimize the need for preservatives for in post-event settings following the intentional release of NIAID Category A, B and C Priority Pathogens or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B and C Priority Pathogens.
Update #2 ·
The objective of this contract is to support the advanced development of candidate products, which consist of a vaccine component in combination with a dry formulation technology (also referred to as solid vaccine formulations), that increase duration of stability and minimize cold chain or preservative requirements. These products will likely be used to minimize the need for preservatives for in post-event settings following the intentional release of NIAID Category A, B and C Priority Pathogens or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B and C Priority Pathogens.
Update #1 ·
The primary objective of this BAA is to support the advanced development of candidate products which consist of a vaccine component in combination with a technology component (a dry formulation technology) to increase stability and minimize cold chain or preservative requirements.
These products will likely be used in post-event settings following the intentional release of NIAID Category A, B and C Priority Pathogens or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B and C Priority Pathogens. Only candidate products against NIAID Category A, B and C Priority Pathogens are eligible under this solicitation.
http://www.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/pages/cata.aspx
Proposals with multiple candidate products using the same vaccine component will be considered, however, proposals with one candidate product are preferred. If more than one candidate product is proposed, a down-select to a single candidate product is required as part of the statement of work (SOW).
Files
| File | Type | Posted |
|---|---|---|
| BAA_-2013174_Amendment_2.pdf | ||
| BAA_NIHAI2013174.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Award Notice | |
| Development of Vaccine Formulations Effective Against NIAID Priority Pathogens | Award Notice |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity